Have a feature idea you'd love to see implemented?
Let us know!
CLRB Cellectar Biosciences Inc
Price (delayed)
$1.58
Market cap
$65.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$31.46M
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations.
Highlights
The company's EPS has surged by 53% YoY and by 41% QoQ
CLRB's quick ratio is up by 47% YoY
Cellectar Biosciences's net income has decreased by 18% YoY but it has increased by 5% QoQ
Key stats
What are the main financial stats of CLRB
Market
Valuations
Earnings
Shares outstanding
41.27M
Market cap
$65.21M
Enterprise value
$31.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$49.73M
EBITDA
-$49.48M
Free cash flow
-$46.57M
Per share
Balance sheet
Liquidity
EPS
-$1.71
Free cash flow per share
-$1.18
Book value per share
$0.42
Revenue per share
$0
TBVPS
$0.95
Total assets
$37.29M
Total liabilities
$20.75M
Debt
$512,750
Equity
$15.16M
Working capital
$15.58M
Debt to equity
0.03
Current ratio
1.77
Quick ratio
1.69
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-163.3%
Return on equity
-798.4%
Return on invested capital
N/A
Return on capital employed
-292.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLRB stock price
How has the Cellectar Biosciences stock price performed over time
Intraday
1.28%
1 week
-21.39%
1 month
-25.12%
1 year
-26.17%
YTD
-42.96%
QTD
-26.17%
Financial performance
How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
$26.34M
Net income
-$49.67M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's operating income has soared by 178% YoY but it has decreased by 13% from the previous quarter
Cellectar Biosciences's net income has decreased by 18% YoY but it has increased by 5% QoQ
Growth
What is Cellectar Biosciences's growth rate over time
Valuation
What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
3.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 53% YoY and by 41% QoQ
The price to book (P/B) is 44% higher than the 5-year quarterly average of 2.6
The equity has grown by 22% from the previous quarter
Efficiency
How efficient is Cellectar Biosciences business performance
The company's return on equity has surged by 57% YoY
The company's return on assets rose by 37% YoY and by 18% QoQ
Dividends
What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLRB.
Financial health
How did Cellectar Biosciences financials performed over time
The total assets is 80% more than the total liabilities
The total assets has soared by 73% YoY and by 27% from the previous quarter
CLRB's quick ratio is up by 47% YoY
The company's debt is 97% lower than its equity
The company's debt to equity has surged by 175% YoY but it fell by 25% QoQ
The equity has grown by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.